Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

Core Viewpoint - The proposed sale of Y-mAbs Therapeutics, Inc. to SERB Pharmaceuticals is under investigation to assess whether the offered price of $8.60 per share adequately reflects the company's value [1]. Group 1: Transaction Details - Shareholders of Y-mAbs will receive $8.60 in cash for each share they own as part of the proposed transaction [1]. - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [3]. Group 2: Legal Investigation - Kahn Swick & Foti, LLC is investigating the adequacy of the proposed sale price and the process leading to this valuation [1]. - The firm is open to discussions regarding legal rights related to the proposed sale, encouraging shareholders to reach out for more information [2].